[Federal Register Volume 71, Number 231 (Friday, December 1, 2006)]
[Notices]
[Page 69590]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-20335]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. Sec.  958(i), the Attorney General shall, 
prior to issuing a registration under this Section to a bulk 
manufacturer of a controlled substance in schedule I or II, and prior 
to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the 
importation of such a substance, provide manufacturers holding 
registrations for the bulk manufacture of the substance an opportunity 
for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on September 12, 2006, Hospira, Inc., 1776 North Centennial Drive, 
McPherson, Kansas 67460-1247, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as an importer of 
Remifentanil (9739), a basic class of controlled substance listed in 
schedule II.
    The company plans to import Phenylacetone to manufacture 
Amphetamine.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic class of controlled substance may 
file comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than January 2, 2007.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substance listed 
in schedule I or II are, and will continue to be, required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 USC 958(a), 21 U.S.C. Sec.  823(a), 
and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.

    Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-20335 Filed 11-30-06; 8:45 am]
BILLING CODE 4410-09-P